Pentapharm Ag

Bristol-myers Squibb Compnay

Kurt F Stocker

Douglas A Triplett

Lars G Svendsen

Per Olsson

Rainer Voegeli

Birgit Hessel

Christian M&uuml;ller

Patrizia Gempeler-Messina

Ernst Wenzel

Jesper Swedenborg

Lennart Str&ouml;mberg

Birger Blomb&auml;ck

Christian Mueller

Disclosed is an adhesive for gluing of biological tissue, in particular human body tissue. The adhesive contains fibrinogen, a substance capable of supplying calcium ions, blood-coagulating factor XIIIa and, as a fibrinogen-splitting substance, a snake-venom enzyme.

Adhesive for the gluing of biological tissues

The method relates to a method for detecting disorders in the protein C system, and in particular for determining the activated blood coagulation factor V with increased stability with respect to decomposition by activated protein C.

Method for the functional detection of disorders in the protein C system

It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyuranus and Psuedonaja genera is most useful in tests for the determination of Lupus Anticoagulant. Based on this, several clotting, chromogenic and immunochromogenic tests have been developed.

Phospholipid dependent prothrombin activator obtained from snake venom

It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyaranus and Psuedonaja genera is most useful in tests for the determination of Lupus Anticoagulant. Based on this, several clotting, chromogenic aria immunochromogenic tests have been developped.

Test for lupus anticoagulant

A method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes belonging to the Elapidae family, the activator comprising an increased plasma clotting activity in the presence of phospholipids and calcium ions; a reduced activity in the presence of Lupus Anticoagulant; an ability to facilitate clotting in a normal clotting time in the presence of platelet poor plasma, the plasma having normal or decreased levels of factor V, VII, VIII, IX, or X; and a major band with a molecular weight of 40,000 to 60,000 daltons on an SDS gel.

Method for the preparation of a phospholipid-dependent prothrombin

The protein fraction from Leguminosae seeds, which is characterized by at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, by relative molecular masses from 3,000 to 30,000 g/mole, by a content of total nitrogen of 14 to 20% and amino nitrogen of 1 to 2% related to the protein content and by further parameters defined in claim 1, is appropriate for the care of skin and for the treatment of inflammatory skin diseases, whereby the protein fraction is generally used as a concentrate of active substances or e.g. as a cream, lotion, emulsion, gel, face mask, powder or plaster.

Protein fraction for cosmetic and dermatology care of the skin

Meizothrombin- and thrombin-inhibiting inhibitors which do not bind bivalent cations and which are used for the anticoagulant pretreatment of blood samples to be used in the determination of the functions and/or changes of state of blood cells and blood corpuscles, and for treating devices and receptacles used for taking and/or receiving blood samples.

Inhibitors for the anticoagulant pretreatment of blood samples

A method and composition for assaying protein C is described. The method comprises reacting a protein C-containing medium with a protein C-activating activator preparation obtained from venom of the snake Agkistrodon contortrix, or venom of another snake species which undergoes an immunological cross-reaction with the venom of Agkistrodon contortrix, to cause maximum activation of protein C and subsequently determining the quantity of activated protein C, said quantity being proportional to the amount of protein C in said medium. Also disclosed is a method and composition for treating thrombotic disorders with the activator preparation and a method of obtaining the activator preparation by culturing of a cloned microorganism.

Protein C activator, methods of preparation and use thereof

A process for the preparation of thrombin-like proteolytic enzymes from snake venoms or fractions thereof comprising contacting the snake venom or fraction thereof with heparin insolubilized by reaction with a water-insoluble carrier in order to bind the thrombin-like enzyme to the insolubilized heparin, removing the undesirable accompanying substances of the snake venom and splitting the thrombin-like enzyme from the insolubilized heparin.

Growing community of inventors

Aesch, Switzerland

Kurt F Stocker